Skye Bioscience, Inc : Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Skye Bioscience (SKYE) Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Acquisition of Bird Rock Bio builds Skye s position as a leading endocannabinoid system-focused pharmaceutical company •New capital funds anticipated Phase 2a glaucoma.
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Skye Bioscience, Inc. (OTCQB: SKYE) has undertaken a strategic initiative that expands the company's resources and technologies focused on developing therapeutic products focused on the endocannabinoid system ("ECS").